These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20222815)
21. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Bosch TM Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231 [TBL] [Abstract][Full Text] [Related]
22. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882 [TBL] [Abstract][Full Text] [Related]
23. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Xu H; Murray M; McLachlan AJ Curr Drug Metab; 2009 Jul; 10(6):643-58. PubMed ID: 19799532 [TBL] [Abstract][Full Text] [Related]
24. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Kunte H; Schmidt S; Eliasziw M; del Zoppo GJ; Simard JM; Masuhr F; Weih M; Dirnagl U Stroke; 2007 Sep; 38(9):2526-30. PubMed ID: 17673715 [TBL] [Abstract][Full Text] [Related]
25. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Campbell RK Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597 [TBL] [Abstract][Full Text] [Related]
26. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results. Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862 [TBL] [Abstract][Full Text] [Related]
27. [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics]. Procacci V; Giovine A; Roberto MG; Ronchi AM; Lasorsa G; Vendemiale G; Stufano N; Altomare E Boll Soc Ital Biol Sper; 1988 Aug; 64(8):731-8. PubMed ID: 3214573 [No Abstract] [Full Text] [Related]
29. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Wang R; Chen K; Wen SY; Li J; Wang SQ Clin Pharmacol Ther; 2005 Jul; 78(1):90-2. PubMed ID: 16003298 [No Abstract] [Full Text] [Related]
30. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Chistiakov DA; Potapov VA; Smetanina SA; Bel'chikova LN; Suplotova LA; Nosikov VV Acta Diabetol; 2011 Sep; 48(3):227-35. PubMed ID: 21611789 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
32. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. Tirkkonen T; Heikkilä P; Huupponen R; Laine K J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928 [TBL] [Abstract][Full Text] [Related]
33. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. Dujic T; Zhou K; Donnelly LA; Leese G; Palmer CNA; Pearson ER Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666 [TBL] [Abstract][Full Text] [Related]
34. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Holstein A; Hahn M; Stumvoll M; Kovacs P Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942 [TBL] [Abstract][Full Text] [Related]
35. Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus? Tatoń J; Piatkiewicz P; Czech A Endokrynol Pol; 2010; 61(1):75-81. PubMed ID: 20205108 [TBL] [Abstract][Full Text] [Related]
36. A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. Li JH; Szczerbinski L; Dawed AY; Kaur V; Todd JN; Pearson ER; Florez JC Diabetes; 2021 Jan; 70(1):293-300. PubMed ID: 33106254 [TBL] [Abstract][Full Text] [Related]